Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

pembrolizumab 45Specimen Handling 45Biopsy 37Magnetic Resonance Spectroscopy 36Paclitaxel 22Nivolumab 21Carboplatin 21Gemcitabine 20Radiosurgery 18Irinotecan 16Ipilimumab 13Cisplatin 13Capecitabine 12130-nm albumin-bound paclitaxel 12trastuzumab deruxtecan 11Taxes 11Pemetrexed 11Cetuximab 11olaparib 10Leucovorin 10Fluorouracil 10Cyclophosphamide 10durvalumab 9Oxaliplatin 9Bevacizumab 9abemaciclib 8X-Rays 8Fulvestrant 8Drug Therapy 8palbociclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × budigalimab × 90 days × Clear all
NCT06119217 2026-05-13

Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Trishula Therapeutics, Inc.

Phase 2 Completed
194 enrolled 16 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡